Corrigendum to “efficacy and Safety of Aripiprazole in Chinese Han Schizophrenia Subjects: A Randomized, Double-Blind, Active Parallel-Controlled, Multicenter Clinical Trial” [schizophr. Res. 157 (1–3) (august 2014) 112–119]
Huafang Li,Jianfeng Luo,ChuanyueWang,Shiping Xie,Xiufeng Xu,XiaopingWang,Wenjuan Yu,Niufan Gu,John M. Kane
DOI: https://doi.org/10.1016/j.schres.2014.07.035
IF: 4.662
2014-01-01
Schizophrenia Research
Abstract:a Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Disorders, Shanghai 200030, China b Department of Health Statistics and Social Medicine, School of Public Health, Fudan University, Shanghai 200032, China c Beijing Anding Hospital, Beijing 100088, China d Nanjing Brain Hospital, Nanjing 210029, China e First Affiliated Hospital of Kunming Medical University, Kunming 650032, China f Renmin Hospital of Wuhan University, Wuhan 430060, China g Zucker Hillside Hospital, The Hofstra North Shore-LIJ School of Medicine, Glen Oaks, NY 11004-1100, USA